VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.

Regulations aiming to lower the cost of vital medicines will instead end up restricting access and disincentivizing R&D.

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Media coverage can help biopharma executives connect with, inform and inspire the public. In this column, ...